Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378038 · ClinicalTrials.gov registry record · Phase 2
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02378038 is a Phase 2 study that was terminated before completion, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 5 participants.
The verdict
NCT02378038, a Phase 2 study, was terminated before completion, sponsored by Sierra Oncology LLC - a GSK company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.
Interventions
- DRUG PNT2258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02378038
The ClinicalTrials.gov registry entry for NCT02378038 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PNT2258 is the first listed.
NCT02378038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02378038 about?
NCT02378038 is a clinical study titled "PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.
What is the current status of trial NCT02378038?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-08. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02378038?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT02378038?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.